Vertex Pharmaceuticals Inc (VRTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $508.25 (-1.57%), Market cap $110.90B, P/E ratio 25.90, 52-week low–high $366.54 ~ $499.17.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients wi
Financial statements, price targets, institutional (13F) holdings and related news for Vertex Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Vertex Pharmaceuticals Inc trades at $508.25 (-1.57%). Real-time quotes and charts are available on BlackAll Trade.
Vertex Pharmaceuticals Inc has a market cap of about $110.90B. Its P/E ratio is 25.90.
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases